Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2012

View Archived Issues

Verva reports on proof-of-concept trial of repurposed drug

Spanish scientists discover new integrin antagonists

Janssen Pharmaceuticals presents novel mGlu2 receptor modulators

Actelion Pharmaceuticals synthesizes novel orexin receptor antagonists

Novel mineralocorticoid receptor antagonists presented

Janssen and Medivir develop novel agents for hepatitis

Gene therapy for choroideremia enters clinic

AstraZeneca TLR7 agonist assessed in four clinical trials

AX-01128 protects kidney transplant function in vivo

Researchers at the CNRS disclose novel inhibitors of tubulin polymerization

Amorfix licenses diagnostic test for Alzheimer's disease to JSW Life Sciences

FDA grants fast track designation to NKTR-181

Takeda transfers TAK-070 to university

Arrowhead Research prepares to file IND

FDA approves Horizant for new indication

Alnylam completes enrollment in phase I ALN-TTR02 study and begins phase II trial

Astellas makes first Dificlir sales in Europe, triggering milestone payment to Optimer

Trovagene and Strand Life Sciences enter collaboration in India and South Asia

U.K.'s NICE issues preliminary opinion on cost-effectiveness of Bronchitol for cystic fibrosis

Ongoing EULAR conference features long-term adalimumab efficacy data in spondylarthritis

FDA extends regulatory review period for ultralong-acting insulins

Sorrento Therapeutics receives new NIH grant

Mesoblast outlines plans to develop stem cell therapies for neurodegenerative diseases

AR-42 gets E.U. orphan drug status for two additional indications

Researchers describe novel monovalent CD28-targeted Fab' antibody fragment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...